Gastrointestinal Effects Nausea affects approximately 28-31% of women at the 12mg dose, with higher rates during dose escalation periods
Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
Ready in minutes, with up to 50g protein per meal
In the SURPASS clinical trials for type 2 diabetes, patients achieved A1c reductions ranging from 1.9% to 2.4% at the highest doses by week 40
The active G6PD enzyme is also referred to as the G form of glucose-6-phosphate dehydrogenase
Please contact our sales team to explore available alternatives
